The impact of individual and combined cardiometabolic risk factors on cardiovascular disease (CVD) incidence.
Coherus plans Humira biosimilar sale at 85% discount – Pharmaceutical Technology
Humira was AbbVie’s blockbuster drug with sales of $21.2bn in 2022. Credit: Coherus BioSciences. Coherus BioSciences has signed a US national distribution agreement with speciality